TIME ZONES
NPGS 2021 Agenda
Following the success of the inaugural 2020 event and valuable feedback from attendees, the 2021 programme will look slightly different - with a focus on broader research topics that are open and accessible to all. Each session will include the opportunity to discuss and ask questions to the presenting experts in neuroblastoma. Alongside these sessions, specialised conversation rooms offer families who have specific interests the opportunity to come together, network and share their experience, covering topics such as CNS relapse and adults living with neuroblastoma.
Friday 5 November
CURRENT RESEARCH - Personalised Medicine and Zero Childhood Cancer Project (including PRISM)
6:00-6:50 London TimeDr. David Ziegler presents on the promising area of personalised medicine and focuses on Australia's PRISM trial which is being extended to include more childhood cancer patients. This session is hosted by NPGS 2021 as part of the Neuroblastoma Australia Family Conference running in parallel.
Moderated by Lucy Jones.
A Q&A will follow.
CURRENT RESEARCH DIRECTIONS: Polyamine Inhibition Projects, CBL0137, BCT-100 and New Discoveries
7:00-7:50 London TimeDr. Murray Norris presents on some of the exciting research being done by Children's Cancer Institute at Randwick including some recently discovered findings. This session is hosted by NPGS 2021 as part of the Neuroblastoma Australia Family Conference running in parallel.
Moderated by Lucy Jones.
A Q&A will follow.
WELCOME
16:00-16:15 London TimeDr. Daniel Morgenstern will welcome you to the event and share a message from Chair of the Children's Oncology Group Neuroblastoma Disease Committee in North America.
COPING WITH DIAGNOSIS
16:15-18:05 London TimeCovering topics including neuroblastoma basics and an overview of standard treatment, this session will provide a deeper understanding of the neuroblastoma landscape for families who are facing a recent diagnosis.
Moderated by Donna Ludwinski.Neuroblastoma basics and terminology with Dr. Ramya Ramanujachar
Overview of treatment for high-risk neuroblastoma with Dr. Daniel Morgenstern
Advances in imaging for neuroblastoma with Dr. Julie Park
Dealing with acute side effects with neuroblastoma nurse practitioner, Jennifer Saggio
Followed by a 45 minute Q&A.
CONVERSATION ROOM: ATRX Mutated Disease
16:15-17:15 London TimeThis conversation room is for parents of children with ATRX mutated neuroblastoma to speak directly about their knowledge and experience. This room will be facilitated by fellow neuroblastoma parent, Sarah Moore, who has advanced knowledge on the topic.
IF TREATMENT DOESN'T GO TO PLAN
18:20-20:10 London TimeFocusing on a common concern in the neuroblastoma community, this session will look at the latest developments in care for relapse and refractory disease, including a parent perspective on the importance of hope.
Moderated by Gavin Lindberg.
- Overcoming refractory disease with Dr. John Maris
- Relapse strategies including a snapshot of current trials with Dr. Pablo Berlanga
- Maximising the potential of MIBG therapy with Dr. Kate Matthay
- What is Hope? with Lara Cady Weberling
Followed by a 45 minute Q&A.
PROGRESS IN NEUROBLASTOMA CLINICAL TRIALS: where we’ve come from & where we’re going
20:45-21:40 London TimeJosiane Demetriou will host this year’s special interest talk with Dr. Toby Trahair, looking at progress in the treatment of neuroblastoma, what the future holds and what can be done to address challenges that remain.
Followed by a Q&A.
Saturday 6 November
MAINTENANCE THERAPIES
15:00-16:20 London TimeThis session will cover the latest updates on common maintenance therapies including the Bivalent Vaccine study and DFMO study.
Moderated by Helen McCarthy-Tennant.
Vaccine study updates with Dr. Shakeel Modak
DFMO study updates with Dr. Giselle Sholler
Options for relapsed neuroblastoma after achieving a response or stabilisation of disease with Dr. Lucas Moreno
Followed by a 45 minute Q&A.
CONVERSATION ROOM - CNS Relapse
15:00-16:00 London TimeThis conversation room is a space for parents to discuss CNS relapse in neuroblastoma. It will be facilitated by Antonia Palmer, neuroblastoma parent and Executive Director of the Kindred Foundation, who has advanced knowledge on the topic.
THE ROLE OF HIGH-DOSE CHEMOTHERAPY IN NEUROBLASTOMA
16:35-17:35 London TimeHigh-dose chemotherapy is a common standard treatment for high-risk neuroblastoma- but there isn’t universal agreement on its continued use. In this session, Dr. Daniel Morgenstern will present a summary of the latest discussions from the recent SIOP meeting, addressing both the pros and cons of this treatment pathway.
Nick Bird will also speak on the parent perspectives around using high-dose chemotherapy for neuroblastoma, and there will be opportunity for open discussion at the end of the talks.
ADVANCES IN IMMUNOTHERAPY FOR RELAPSE/REFRACTORY
17:50-19:25 London TimeCould immunotherapy be a key to treating cases of relapse or refractory disease? Experts will present the latest developments in ongoing trials and new combination therapy studies that hope to answer this question.
Moderated by Nick Bird.
Updates on Naxitamab and Omburtamab with Dr. Jaume Mora
Chemoimmunotherapy combinations with Dr. Rajen Mody
Exploring the role of anti-CD47 with Dr. Robbie Majzner
Followed by a 45 minute Q&A.
SURVIVORSHIP
19:40-21:00 London TimeDr. Lisa Diller provides an overview of issued faced in this Q&A session focused on the hopes and challenges of life after treatment. In addition, neuroblastoma survivors will join, led by Pat Tallungan, to share their experiences.
CLOSING REMARKS
21:00-21:15 London TimeSymposium Host Dr. Daniel Morgenstern will close this year’s event, with a montage of the children from around the world who we are here to support and champion.